#USA #Detroit #Drug Development #SciTech Development #Ken Massey

SciTech Development Welcomes Dr. Ken Massey as New Strategic Operations Advisor

SciTech Development, based in Michigan, has made a significant addition to its team by welcoming Dr. Ken Massey as its new Strategic Operations Advisor. This move is seen as a strategic enhancement to the company's leadership, as Dr. Massey brings a wealth of experience from his extensive background in drug development and pharmaceutical sciences.

Dr. Massey is currently the Senior Director of Venture Development and an Adjunct Professor of Pharmacology at Wayne State University (WSU). His career is marked by key roles both in academia and the pharmaceutical industry, including notable tenures at Pfizer. While at Pfizer, he served as a scientist and director for the clinical cardiovascular group, where he guided various drug development programs through the rigorous FDA approval process. His expertise encompasses all phases of drug research and development, making him a valuable asset to SciTech’s mission.

In addition to his industry experience, Dr. Massey has also contributed to education as an assistant professor at the University of Michigan Medical School, where he held joint appointments in Anesthesiology and Pharmacology. His versatility is further exemplified by his leadership as managing director at LifeLine Ventures, a role that married innovation with commercial viability.

Expressing his enthusiasm about his new role, Dr. Massey stated, “I am excited to join the talented SciTech Development team as the Strategic Operations Advisor. I look forward to contributing to the company's growth and success by driving operational excellence and supporting our strategic initiatives.” He has been familiar with SciTech and its leading compound, ST-001, for many years, seeing potential for its success as it advances through clinical trials.

ST-001 is a nanoparticle formulation designed to enhance the delivery and efficacy of fenretinide, aiming to treat challenging cancers such as T-Cell Non-Hodgkin Lymphoma. As the company progresses through its clinical studies, Dr. Massey’s strategic direction is expected to facilitate not only the advancement of ST-001 but also the expansion of SciTech’s oncology portfolio. This aligns with the long-term vision of providing safe and effective treatment options for patients grappling with metastatic diseases.

Chief Executive Officer Earle Holsapple expressed confidence in Dr. Massey’s appointment, stating, “With Dr. Massey's appointment, SciTech continues to strengthen its capabilities in strategic planning and operational execution as we move forward with our clinical studies and pipeline expansion.” The CEO emphasized the company's unwavering commitment to innovation in the field of cancer treatment and the importance of Dr. Massey’s expertise to navigate the company toward future growth and success.

SciTech Development remains dedicated to transforming cancer care through pioneering new therapeutics and improving outcomes for patients facing difficult-to-treat cancers. Dr. Massey’s joining marks a new chapter in this vision, underlining the company's proactive approach in assembling a distinguished leadership team.

For more information about SciTech Development and its initiatives, visit www.SciTechSDP.com.